

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 7, 2023

Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP)

Company name: SHIMADZU CORPORATION
 Listing: Tokyo Stock Exchange
 Securities code: 7701
 URL: <https://www.shimadzu.co.jp>
 Representative: Yasunori Yamamoto, President and Representative Director
 Inquiries: Koumei Arakane, Corporate Officer, General Manager, Finance and Accounting Dept.
 Telephone: +81-75-823-1128
 Scheduled date to file quarterly securities report: November 8, 2023
 Scheduled date to commence dividend payments: December 4, 2023
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2023 (from April 1, 2023 to September 30, 2023)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended								
September 30, 2023	239,514	7.9	32,505	12.4	35,851	8.2	26,550	8.4
September 30, 2022	221,893	9.8	28,912	0.3	33,140	12.9	24,500	19.6

Note: Comprehensive income For the six months ended September 30, 2023: ¥39,500 million [14.4%]
 For the six months ended September 30, 2022: ¥34,539 million [54.1%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2023	90.09	—
September 30, 2022	83.15	—

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
September 30, 2023	635,089	453,483	71.4
March 31, 2023	618,869	423,499	68.4

Reference: Equity
 As of September 30, 2023: ¥453,478 million
 As of March 31, 2023: ¥423,499 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2023	–	22.00	–	32.00	54.00
Fiscal year ending March 31, 2024	–	24.00			
Fiscal year ending March 31, 2024 (Forecast)			–	34.00	58.00

Note: Revisions to the forecast of cash dividends most recently announced: Yes

3. Consolidated earnings forecast for the fiscal year ending March 31, 2024 (April 1, 2023 to March 31, 2024)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2024	510,000	5.8	73,000	7.0	74,000	4.4	55,000	5.7	186.62

Note: Revisions to the earnings forecast most recently announced: Yes

* For matters related to the above forecast, please refer to page 5, “Consolidated Outlook.”

*** Notes**

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None
- (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None
- (3) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
 - (ii) Changes in accounting policies due to other reasons: None
 - (iii) Changes in accounting estimates: None
 - (iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2023	296,070,227 shares
As of March 31, 2023	296,070,227 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2023	1,346,851 shares
As of March 31, 2023	1,399,245 shares

(iii) Average number of shares outstanding during the period

Six months ended September 30, 2023	294,697,317 shares
Six months ended September 30, 2022	294,662,375 shares

* Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters

1. The consolidated earnings forecast for the fiscal year ending March 31, 2024 that was announced on May 10, 2023 has been revised in this report.
2. The above forecast was calculated based on information available on the date this report was released. Actual results may vary from forecast values, due to various factors in the future. For matters related to the above forecast, please refer to page 5, "Consolidated Outlook."

Table of Contents**Index**

1. Qualitative Information on Quarterly Consolidated Financial Statements	2
(1) Operating Results	2
(2) Consolidated Outlook.....	5
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto	6
(1) Quarterly Consolidated Balance Sheets	6
(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income.....	8
(3) Quarterly Consolidated Statement of Cash Flows.....	10
(4) Notes on Consolidated Financial Statements	12
Notes on Going-Concern Assumptions	12
Notes on the Event of Significant Fluctuations in Shareholders' Capital.....	12
Segment Information.....	12
3. Supplemental Information	14

1. Qualitative Information on Quarterly Consolidated Financial Statements

(1) Operating Results

During the six months ended September 30, 2023, uncertainty remained in the global economy due to such factors as increasing economic downside risk hastened by various countries imposing austerity measures and the protracted Russian invasion of Ukraine and the economic slowdown in China.

Given such a business environment, there was an increase in sales of the key models of liquid chromatographs, mass spectrometer systems, and gas chromatographs in the Healthcare and Green domains, in addition to a recovery in production resulting from an easing of parts and materials shortages. We also proceeded with price revision in parallel with growth investments including those in human resources, R&D, and capital equipment, and worked to improve profitability.

During the six months ended September 30, 2023, given the above and the buoying effect of the increasingly weaker yen, on a consolidated basis, Shimadzu posted net sales of 239,514 million yen (a year-on-year increase of 7.9%), operating profit of 32,505 million yen (a year-on-year increase of 12.4%), ordinary profit of 35,851 million yen (a year-on-year increase of 8.2%), and profit attributable to owners of parent of 26,550 million yen (a year-on-year increase of 8.4%).

The results for reportable business segments were as follows.

I. Analytical & Measuring Instruments

In the Analytical & Measuring Instruments segment, sales increased both in Japan and outside Japan. Liquid chromatographs and mass spectrometer systems increased in the Healthcare domain, gas chromatographs increased in the Green domain, and testing machines increased in the Material domain.

There was also a contribution from Shimadzu Diagnostics Corporation, which became a consolidated subsidiary in September 2022. In addition, there was a recovery in production due to an easing of parts and materials shortages and a reactionary increase from lockdowns in China in the previous year.

As a result, the Analytical & Measuring Instruments segment posted net sales of 158,728 million yen (a year-on-year increase of 12.2%), with operating profit of 26,611 million yen (a year-on-year increase of 11.6%) due to increased net sales and other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for First Six Months of FY 2022 (millions of yen)	Consolidated Results for First Six Months of FY 2023 (millions of yen)	Percent Increase/Decrease (%)	Overview
Japan	50,082	54,218	8.3	Sales of liquid chromatographs for pharmaceutical applications, mass spectrometer systems for academia, and mass spectrometer systems and testing machines for chemistry applications increased, despite a decrease in COVID-19-related products. There was a contribution from Shimadzu Diagnostics Corporation, which became a consolidated subsidiary in September 2022.
North America	15,864	16,286	2.7	Although sales of liquid chromatographs for functional food applications decreased, sales of mass spectrometer systems and gas chromatographs for atmospheric monitoring increased.
Europe	14,541	17,932	23.3	Sales of liquid chromatographs and mass spectrometer systems for pharmaceutical applications and gas chromatographs for new energy development increased. Sales of liquid chromatographs and mass spectrometer systems for academia increased.
China	36,049	39,665	10.0	There was a reactionary increase from the lockdowns in the previous year, and sales of liquid chromatographs, mass spectrometer systems, and gas chromatographs for academia increased.
Other Asian countries	18,556	21,818	17.6	Sales of liquid chromatographs and mass spectrometer systems for pharmaceutical and chemistry applications increased.

II. Medical Systems

In the Medical Systems segment, sales decreased in Japan, but increased outside Japan. In Japan, sales were affected by restrained investment by medical institutions due to rising prices, a decrease in the supplementary budget, and a reactionary decline in large-volume projects. Meanwhile, overseas sales of angiography systems increased in the U.S. and India, and so did those of new fluoroscopy systems manufactured locally for the Chinese market.

As a result, the Medical Systems segment posted net sales of 33,399 million yen (a year-on-year decrease of 11.3%), with operating profit of 1,632 million yen (a year-on-year decrease of 43.1%) due to decreased net sales and other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for First Six Months of FY 2022 (millions of yen)	Consolidated Results for First Six Months of FY 2023 (millions of yen)	Percent Increase/Decrease (%)	Overview
Japan	20,464	15,900	(22.3)	Sales were affected by restrained investment by medical institutions due to rising prices, a decrease in the supplementary budget, and a reactionary decline in large-volume projects.
North America	5,067	5,005	(1.2)	Although angiography systems increased, sales decreased slightly as medical institutions restrained investment due to rising prices and labor costs.
Europe	1,968	2,004	1.8	Although sales of fluoroscopy systems decreased, sales of mobile X-ray systems increased due to large-volume projects.
China	2,322	3,044	31.1	Sales of new fluoroscopy systems manufactured locally for the Chinese market increased.
Other Asian countries	3,612	3,224	(10.7)	Sales decreased due to a rebound from large-volume projects in the previous year although sales of angiography systems increased in India.

III. Industrial Machinery

In the Industrial Machinery segment, sales decreased in Japan, but increased outside Japan. In Japan, sales of turbomolecular pumps for use in semiconductor manufacturing equipment decreased despite an increase in hydraulic equipment for the construction machinery and agricultural equipment fields and industrial furnaces for EV ceramic manufacturing. Overseas, sales of turbomolecular pumps for use in thin-film manufacturing equipment used in solar cells and highly energy efficient construction glass increased due to a rising consciousness toward the environment.

As a result, the Industrial Machinery segment posted net sales of 30,810 million yen (a year-on-year increase of 1.5%), with operating profit of 3,250 million yen (a year-on-year increase of 25.3%) due to increased net sales and other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for First Six Months of FY 2022 (millions of yen)	Consolidated Results for First Six Months of FY 2023 (millions of yen)	Percent Increase/Decrease (%)	Overview
Japan	12,977	12,516	(3.6)	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment decreased despite an increase in hydraulic equipment for the construction machinery and agricultural equipment fields and industrial furnaces for EV ceramic manufacturing.
North America	4,282	4,058	(5.2)	Hydraulic equipment sales increased, but turbomolecular pumps for use in semiconductor manufacturing equipment decreased.
Europe	2,017	2,318	14.9	Sales of turbomolecular pumps for use in thin-film manufacturing equipment for producing glass used in construction materials increased.
China	8,300	9,196	10.8	Sales of turbomolecular pumps for use in thin-film manufacturing equipment for producing solar cells and glass used in construction materials increased due to an increase in demand for renewable energy. In addition, sales of industrial furnaces for EV ceramic manufacturing increased.
Other Asian countries	2,724	2,563	(5.9)	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment decreased.

IV. Aircraft Equipment

In the Aircraft Equipment segment, sales increased both in Japan and outside Japan. In Japan, sales in the defense field increased due to increased demand for parts for repair. Overseas, airframe production increased further, and sales increased in the commercial aircraft equipment field in line with the increase in air passenger demand.

As a result, the Aircraft Equipment segment posted net sales of 13,175 million yen (a year-on-year increase of 25.5%), with operating profit of 1,353 million yen (a year-on-year increase of 321.4%) due to increased net sales and profitability improvement.

Net sales broken down by major regions are indicated below.

	Consolidated Results for First Six Months of FY 2022 (millions of yen)	Consolidated Results for First Six Months of FY 2023 (millions of yen)	Percent Increase/Decrease (%)	Overview
Japan	7,525	9,216	22.5	Sales in the defense field increased due to increased demand for parts for repair.
North America	2,585	3,713	43.6	Items loaded onto aircraft increased in the commercial aircraft equipment field due to increased production by aircraft manufacturers.

V. Other

Other business segments posted net sales of 3,399 million yen (a year-on-year increase of 77.1%) and operating profit of 405 million yen (a year-on-year increase of 42.8%).

(2) Consolidated Outlook

We have upwardly revised our consolidated earnings forecast announced on May 10, 2023, taking into consideration the progress of operating results in the six months ended September 30, 2023, and revision of the foreign exchange rate assumption, among others.

(Millions of yen)

	Consolidated Earnings Forecast for the fiscal year ending March 31, 2024	Percent Increase/Decrease Year-on-Year	(Reference) Previous Forecast
Net Sales	510,000	5.8%	500,000
Operating Profit	73,000	7.0%	71,000
Ordinary Profit	74,000	4.4%	71,000
Profit Attributable to Owners of Parent	55,000	5.7%	53,000

Note: The forecasted results above were calculated based on information available on the date this report was released. Actual results may vary from forecast values, due to various factors in the future.

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2023	As of September 30, 2023
Assets		
Current assets		
Cash and deposits	158,847	162,121
Notes and accounts receivable - trade, and contract assets	131,242	123,354
Securities	425	415
Merchandise and finished goods	72,332	83,945
Work in process	26,505	27,970
Raw materials and supplies	29,257	32,170
Other	15,115	15,880
Allowance for doubtful accounts	(2,217)	(2,199)
Total current assets	431,509	443,659
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	54,954	55,479
Machinery, equipment and vehicles, net	8,823	9,016
Land	22,040	22,367
Leased assets, net	2,108	2,181
Construction in progress	2,124	3,053
Other, net	22,942	24,914
Total property, plant and equipment	112,992	117,011
Intangible assets		
Goodwill	4,947	4,876
Other	12,015	12,132
Total intangible assets	16,963	17,008
Investments and other assets		
Investment securities	15,145	15,451
Long-term loans receivable	174	190
Retirement benefit asset	21,818	22,043
Deferred tax assets	15,692	14,518
Other	4,941	5,284
Allowance for doubtful accounts	(368)	(78)
Total investments and other assets	57,403	57,410
Total non-current assets	187,360	191,429
Total assets	618,869	635,089

(Millions of yen)

	As of March 31, 2023	As of September 30, 2023
Liabilities		
Current liabilities		
Notes and accounts payable - trade	66,713	54,523
Short-term borrowings	1,400	1,634
Lease liabilities	3,237	3,599
Accounts payable - other	15,928	16,315
Income taxes payable	10,320	7,501
Contract liabilities	50,158	50,006
Provision for bonuses	13,627	13,072
Provision for bonuses for directors (and other officers)	366	263
Provision for share awards	115	–
Other	10,519	11,087
Total current liabilities	172,387	158,006
Non-current liabilities		
Long-term borrowings	132	99
Lease liabilities	6,499	7,143
Provision for retirement benefits for directors (and other officers)	141	144
Retirement benefit liability	14,222	14,742
Provision for share awards	–	17
Other	1,986	1,451
Total non-current liabilities	22,982	23,599
Total liabilities	195,370	181,605
Net assets		
Shareholders' equity		
Share capital	26,648	26,648
Capital surplus	34,910	34,910
Retained earnings	336,066	352,987
Treasury shares	(1,210)	(1,103)
Total shareholders' equity	396,415	413,443
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,829	6,323
Foreign currency translation adjustment	15,656	28,324
Remeasurements of defined benefit plans	5,597	5,386
Total accumulated other comprehensive income	27,084	40,035
Non-controlling interests	–	4
Total net assets	423,499	453,483
Total liabilities and net assets	618,869	635,089

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income**Quarterly Consolidated Statement of Income (Cumulative)**

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Net sales	221,893	239,514
Cost of sales	129,649	135,117
Gross profit	92,243	104,397
Selling, general and administrative expenses	63,331	71,891
Operating profit	28,912	32,505
Non-operating income		
Interest income	158	659
Dividend income	160	194
Insurance claim income	98	73
Foreign exchange gains	3,747	2,580
Subsidy income	218	60
Other	380	584
Total non-operating income	4,765	4,153
Non-operating expenses		
Interest expenses	133	141
Other	404	665
Total non-operating expenses	537	806
Ordinary profit	33,140	35,851
Extraordinary income		
Gain on sale of non-current assets	17	118
Gain on sale of investment securities	19	49
Insurance claim income	891	–
Total extraordinary income	928	167
Extraordinary losses		
Loss on disposal of non-current assets	86	116
Loss on liquidation of business	607	–
Loss on valuation of investment securities	2	–
Total extraordinary losses	696	116
Profit before income taxes	33,372	35,903
Income taxes - current	9,972	8,590
Income taxes - deferred	(1,100)	763
Total income taxes	8,872	9,353
Profit	24,500	26,549
Loss attributable to non-controlling interests	–	(0)
Profit attributable to owners of parent	24,500	26,550

Quarterly Consolidated Statement of Comprehensive Income (Cumulative)

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Profit	24,500	26,549
Other comprehensive income		
Valuation difference on available-for-sale securities	(879)	494
Foreign currency translation adjustment	10,933	12,667
Remeasurements of defined benefit plans, net of tax	(15)	(211)
Total other comprehensive income	10,039	12,951
Comprehensive income	34,539	39,500
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	34,539	39,501
Comprehensive income attributable to non-controlling interests	—	(0)

(3) Quarterly Consolidated Statement of Cash Flows

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Cash flows from operating activities		
Profit before income taxes	33,372	35,903
Depreciation	8,500	9,171
Loss on liquidation of business	607	–
Insurance claim income	(891)	–
Increase (decrease) in allowance for doubtful accounts	(182)	(538)
Increase (decrease) in provision for bonuses	(424)	(765)
Increase (decrease) in provision for bonuses for directors (and other officers)	(126)	(108)
Increase (decrease) in net defined benefit asset and liability	(354)	(487)
Interest and dividend income	(319)	(853)
Interest expenses	133	141
Foreign exchange losses (gains)	(2,539)	(2,485)
Loss (gain) on sale and valuation of investment securities	(16)	(49)
Loss (gain) on sale and retirement of property, plant and equipment	68	(2)
Decrease (increase) in trade receivables	16,602	13,601
Decrease (increase) in inventories	(10,413)	(9,873)
Increase (decrease) in trade payables	(10,483)	(16,343)
Increase (decrease) in contract liabilities	3,829	(4,918)
Other, net	(3,268)	295
Subtotal	34,095	22,684
Interest and dividends received	319	890
Interest paid	(133)	(139)
Proceeds from insurance income	346	–
Income taxes paid	(11,922)	(11,631)
Net cash provided by (used in) operating activities	22,705	11,804
Cash flows from investing activities		
Purchase of non-current assets	(8,503)	(7,415)
Proceeds from sale of non-current assets	147	218
Purchase of investment securities	(1)	(323)
Proceeds from sale of investment securities	41	74
Loan advances	(26)	(30)
Proceeds from collection of loans receivable	22	29
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(10,439)	–
Other, net	(993)	285
Net cash provided by (used in) investing activities	(19,752)	(7,161)

(Millions of yen)

	Six months ended September 30, 2022	Six months ended September 30, 2023
Cash flows from financing activities		
Proceeds from short-term borrowings	–	237
Repayments of short-term borrowings	(0)	–
Repayments of long-term borrowings	(38)	(36)
Dividends paid	(8,477)	(9,421)
Repayments of lease liabilities	(2,274)	(2,380)
Decrease (increase) in treasury shares	35	106
Other, net	–	4
Net cash provided by (used in) financing activities	(10,755)	(11,488)
Effect of exchange rate change on cash and cash equivalents	9,369	9,965
Net increase (decrease) in cash and cash equivalents	1,567	3,118
Cash and cash equivalents at beginning of period	155,319	153,734
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	–	441
Cash and cash equivalents at end of period	156,886	157,295

(4) Notes on Consolidated Financial Statements**Notes on Going-Concern Assumptions**

Not applicable.

Notes on the Event of Significant Fluctuations in Shareholders' Capital

Not applicable.

Segment Information

1 Information on net sales and operating profit (loss) by reportable segment

From April 1 to September 30 of fiscal year ended March 31, 2023

(Millions of yen)

	Reportable segment					Other	Total	Adjustments	Amounts reported on the quarterly statements of income
	Analytical & Measuring Instruments	Medical Systems	Industrial Machinery	Aircraft Equipment	Total				
Net sales									
Sales to customers	141,477	37,637	30,359	10,498	219,973	1,919	221,893	–	221,893
Inter-segment sales	24	29	32	18	104	1,108	1,212	(1,212)	–
Total	141,502	37,666	30,391	10,517	220,077	3,028	223,105	(1,212)	221,893
Operating profit	23,848	2,870	2,594	321	29,634	284	29,918	(1,006)	28,912

From April 1 to September 30 of fiscal year ending March 31, 2024

(Millions of yen)

	Reportable segment					Other	Total	Adjustments	Amounts reported on the quarterly statements of income
	Analytical & Measuring Instruments	Medical Systems	Industrial Machinery	Aircraft Equipment	Total				
Net sales									
Sales to customers	158,728	33,399	30,810	13,175	236,114	3,399	239,514	–	239,514
Inter-segment sales	14	11	34	16	77	1,244	1,322	(1,322)	–
Total	158,742	33,411	30,845	13,192	236,192	4,644	240,836	(1,322)	239,514
Operating profit	26,611	1,632	3,250	1,353	32,848	405	33,254	(748)	32,505

<Related Information>

Information on the Amount of Net Sales by Geographical Segment

From April 1 to September 30 of fiscal year ended March 31, 2023

(Millions of yen)						
Japan	The Americas	Europe	China	Other Asian countries	Other	Total
92,965	31,377	18,862	46,680	24,938	7,068	221,893

From April 1 to September 30 of fiscal year ending March 31, 2024

(Millions of yen)						
Japan	The Americas	Europe	China	Other Asian countries	Other	Total
95,247	33,543	22,397	51,929	27,686	8,710	239,514

Note: Main countries and regions included in the geographical segments other than Japan

The Americas: U.S.A.

Europe: U.K., Germany

China: China

Other Asian countries: India, Southeast Asia, South Korea, Taiwan

Other: Australia, Middle East, Africa

3. Supplemental Information

Overview of Financial Results for the First Six Months of the Fiscal Year Ending March 2024

Row No.			Consolidated Results for First Six Months of FY 2022	Consolidated Results for First Six Months of FY 2023	Year on Year		FY 2022	FY 2023
			Results	Results	Increase/Decrease	Percent Increase/Decrease	Results	Forecast
1	Net Sales	millions of yen	221,893	239,514	17,621	7.9%	482,240	510,000
2	Net Sales (Analytical & Measuring Instruments)	millions of yen	141,477	158,728	17,250	12.2%	314,668	–
3	Net Sales (Medical Systems)	millions of yen	37,637	33,399	(4,238)	(11.3)%	75,876	–
4	Net Sales (Industrial Machinery)	millions of yen	30,359	30,810	451	1.5%	62,982	–
5	Net Sales (Aircraft Equipment)	millions of yen	10,498	13,175	2,677	25.5%	23,985	–
6	Net Sales (Other)	millions of yen	1,919	3,399	1,479	77.1%	4,726	–
7	Net Sales by Region (Japan)	millions of yen	92,965	95,247	2,281	2.5%	211,124	–
8	Net Sales by Region (Outside Japan)	millions of yen	128,927	144,266	15,339	11.9%	271,115	–
9	Net Sales (The Americas)	millions of yen	31,377	33,543	2,165	6.9%	65,441	–
10	Net Sales (Europe)	millions of yen	18,862	22,397	3,534	18.7%	41,684	–
11	Net Sales (China)	millions of yen	46,680	51,929	5,249	11.2%	96,747	–
12	Net Sales (Other Asian Countries)	millions of yen	24,938	27,686	2,747	11.0%	52,202	–
13	Net Sales (Other)	millions of yen	7,068	8,710	1,641	23.2%	15,040	–
14	Operating Profit	millions of yen	28,912	32,505	3,592	12.4%	68,219	73,000
15	Ordinary Profit	millions of yen	33,140	35,851	2,710	8.2%	70,882	74,000
16	Profit Attributable to Owners of Parent	millions of yen	24,500	26,550	2,049	8.4%	52,048	55,000
17	Earnings per Share (FY 2023 Q2)	Yen	83.15	90.09	–	–	176.64	186.62
18	Dividend per Share	Yen	22.00	24.00	–	–	54.00	58.00
19	Capital Equipment Investment	millions of yen	12,080	12,061	(19)	(0.2)%	22,512	25,000
20	Depreciation and Amortization	millions of yen	8,500	9,171	670	7.9%	17,524	18,000
21	Total Assets	millions of yen	596,234	635,089	38,855	6.5%	618,869	–
22	Net Assets	millions of yen	410,066	453,483	43,417	10.6%	423,499	–
23	Equity Ratio	%	68.3	71.4	–	–	68.4	–
24	Number of All Group Employees	Employees	13,869	14,203	334	–	13,898	–
25	Number of Consolidated Subsidiaries	Companies	78	79	–	–	78	–
26	Japan	Companies	23	24	–	–	23	–
27	Outside Japan	Companies	55	55	–	–	55	–